Clinical trial
Ologen (OculusGen)-Glaucoma MMC Control Trial in India
NCT00449098 · Pro Top & Mediking Company Limited, Industry · Unknown status
Key facts
| NCT number | NCT00449098 |
|---|---|
| Title | Ologen (OculusGen)-Glaucoma MMC Control Trial in India |
| Official title | Comparative Study of the Safety and Effectiveness Between Ologen (OculusGen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery |
| Lead sponsor | Pro Top & Mediking Company Limited, Industry |
| Status | Unknown status |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Glaucoma |
| Intervention type | Device, Drug |
| Interventions | OculusGen Biodegradable Collagen Matrix Implant, Trabeculectomy with MMC |
| Enrollment | 40 |
| Start date | Jan 1, 2007 |
| Primary completion | Oct 1, 2011 |
| Completion | Oct 1, 2011 |
| First posted | Mar 19, 2007 |
| Last update posted | Oct 7, 2011 |
| Countries | India |
At a glance
- 1–9 Study sites
- No Results posted
- 1–9 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: